Dr. Stephen Horgan, M.B., B.CH., PH.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 50 Cherry Hill Rd, Parsippany, NJ 07054 Phone: 973-971-7048 |
Jinhan Chi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 Baldwin Rd Ste 105, Parsippany, NJ 07054 Phone: 973-402-0070 |
Kamal Patel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1081 Parsippany Blvd, Suite 102, Parsippany, NJ 07054 Phone: 973-917-3555 Fax: 973-917-3553 |
News Archive
LUMEDX Corporation, a leading provider of vendor-neutral, integrated cardiovascular imaging and information systems (CVIS), announced the successful implementation of CardioInventory at nine Iowa Health Systems (IHS) affiliate hospitals. The final go-live at St. Luke's Medical Center in Cedar Rapids represents an important milestone in the ongoing installation of a centralized, enterprise-wide LUMEDX cardiovascular image- and data-management system for Iowa Health System.
Women who watch their weight and closely follow a Mediterranean-style diet high in vegetables, vegetable oils, fish and beans may increase their chance of becoming pregnant, according to dietitians at Loyola University Health System.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest Diagnostics, the world's leading provider of diagnostic information services, to expand COVID-19 antibody testing to more than 20 Quest laboratories across the U.S.
Agfa HealthCare announced today that Summa Health System has selected the company's digital radiography technologies, including the DX-D Retrofit and DX-D 100 mobile DR systems, DX-M multi-plate CR, and CR 30-X single plate table top CR, in combination with an upgrade of Agfa HealthCare's patented MUSICA image processing software through Agfa HealthCare's Digital Radiography Upgrade Program.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers' diarrhea.
› Verified 4 days ago